Trial Profile
Zenapax-activated peptide immunotherapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Daclizumab; PEP-3-KLH conjugate vaccine; Temozolomide
- Indications Glioblastoma
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ZAP IT
- 29 Mar 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2013 as reported by ClinicalTrials.gov.
- 28 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 06 Jun 2010 Basiliximab added as investigational drug as reported by ClinicalTrials.gov.